55 results
Page 3 of 3
F-1
5xgu txe9vrkac
8 Mar 21
Registration statement (foreign)
9:50pm
6-K
EX-99.1
8lzns60dbgouq1yxc
16 Nov 20
Silence Therapeutics Presents Positive Pre-Clinical Data for SLN360 for the Treatment of Elevated Lipoprotein(a) at American Heart Association 2020
7:00am
6-K
EX-99.1
k7zxs97b8nye nz8sf
2 Nov 20
Silence Therapeutics Appoints Dr. Marie Wikström Lindholm to its
7:31am
POS AM
v1ro5jr
23 Sep 20
Prospectus update (post-effective amendment)
4:47pm
6-K
EX-99.2
wof2xdpp iv5fgn2
14 Sep 20
Silence Therapeutics Appoints Mark Rothera as President and Chief Executive Officer
7:10am
6-K
EX-99.1
7ff8q79
14 Sep 20
Silence Therapeutics Appoints Mark Rothera as President and Chief Executive Officer
7:10am
S-8
2939zvmste1c7 da
9 Sep 20
Registration of securities for employees
2:36pm
6-K
EX-99.1
00h drbna84
8 Sep 20
Silence Therapeutics Provides Research and Development Update
7:35am
424B4
sbd5gf0 atih
8 Sep 20
Prospectus supplement with pricing info
7:31am
F-1/A
4og45v52q
26 Aug 20
Registration statement (foreign) (amended)
3:03pm
F-1
EX-10.6
zkqlri ijvo7
20 Aug 20
Registration statement (foreign)
4:50pm
F-1
y9iylle4 gybfcn
20 Aug 20
Registration statement (foreign)
4:50pm
DRS/A
zv2ghz33djvrwv
31 Jul 20
Draft registration statement (amended)
12:00am
DRS
cw3ddx20o581q6vhbc
22 Jun 20
Draft registration statement
12:00am
DRS
EX-10
loi1718w7pnwza
22 Jun 20
Draft registration statement
12:00am